AMLprofiler Launch Event
On Wednesday the 16th of February 2011, Skyline Diagnostics has officially launched the AMLprofiler for diagnosis of Acute Myeloid Leukemia.
Professors Bob Löwenberg (CSO) and Peter van der Spek, as well as Skyline’s CEO Henk Viëtor gave inspiring presentations for the press, invitees and the Skyline team in Podium 0950 in Rotterdam. CE-marking is expected in Q1 2010, whereas a multi-site trial prepares for FDA approval of the AMLprofiler in 2012.
News overview
-
A 7-hill Skyline
-
Skyline attends the ESH-EHA Workshop
-
Skyline participates in CTMM Annual meeting 2011
-
Skyline Diagnostics and Clavis Pharma to collaborate
-
Research Collaboration with Janssen
-
Skyline at the EHA 2011 Exhibition
-
West Midlands Regional Genetics Laboratory spent three days being trained by Skyline Diagnostics
-
Skyline at EHA 2011
-
High school pupils visit Skyline
-
EU Launch AMLprofiler
-
Innovatiekrediet
-
Skyline in DiagNed
-
AMLprofiler Launch Event
-
Mibiton grant
-
NPM1 license
Dr. Molewaterplein 50, Suite Ee1971, 3015 GE Rotterdam. The Netherlands, Europe. Phone: +31 (0)10 7038410. Fax: +31 (0)10 7043076. E-mail: info@skyline-diagnostics.com
